Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome
Status: | Recruiting |
---|---|
Conditions: | Anemia |
Therapuetic Areas: | Hematology |
Healthy: | No |
Age Range: | 2 - 40 |
Updated: | 1/17/2019 |
Start Date: | January 12, 2018 |
End Date: | January 2022 |
Contact: | Mitchell S Cairo, MD |
Email: | mitchell_cairo@nymc.edu |
Phone: | 9145972150 |
A Phase II Study to Determine the Safety of Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome
This study evaluates the safety of defibrotide in subjects with sickle cell disease
(SCD)-associated acute chest syndrome (ACS).
(SCD)-associated acute chest syndrome (ACS).
Inclusion Criteria:
- SCD-associated ACS with the presence of any two or more of the following signs not
explained by other etiologies: Fever, Chest pain, Cough, Dyspnea, Tachypnea for age,
Pulmonary infiltrate on CXR and/or Chest CT scan, Decreased O2 saturation with or
without oxygen supplement;
- Age 2 to 40 years of age;
- Homozygous Hemoglobin S Disease, Hemoglobin SC Disease or Hemoglobin S 0/+
thalassemia;
- Informed consent/assent;
- Consent of patient/parent within ≤72 hours after inpatient admission for
SCD-associated ACS.
- Females of childbearing age will have a negative pregnancy test.
Exclusion Criteria:
- Current Grade III or IV hemorrhage;
- Previous hypersensitivity reaction to defibrotide;
- Current systemic anti-coagulant therapy and/or fibrinolytic therapy;
- Consent of patient/parent greater than 72 hours of inpatient admission for
SCD-associated ACS;
- No signed informed consent
We found this trial at
1
site
40 Sunshine Cottage Road
Valhalla, New York 10595
Valhalla, New York 10595
(914) 594-4000
Principal Investigator: Mitchell S. Cairo, MD
Phone: 914-594-2150
New York Medical College The College was founded in 1860 by a group of New...
Click here to add this to my saved trials